Transmembranous transport of drugs: implications for kinetics and drug action.
Stratmann
G
G
Institute for Clinical Pharmacology, University Hospital, Frankfurt am Main, Germany.
Jarosch
A
A
Sulzbacher
A
A
Schüler
R
R
Kümel
G
G
Woodcock
B G
BG
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology*; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics* / Q000494:pharmacology; D001693:Biological Transport, Active / Q000187:drug effects; D018938:Caco-2 Cells / Q000166:cytology / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000502:physiology*; D018922:HL-60 Cells / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D008353:Mannitol / Q000378:metabolism; D009961:Orosomucoid / Q000378:metabolism / Q000494:pharmacology; D013237:Stereoisomerism; D014700:Verapamil / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D014750:Vincristine / Q000493:pharmacokinetics* / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000972:Antineoplastic Agents, Phytogenic; D002121:Calcium Channel Blockers; D009961:Orosomucoid; D008353:Mannitol; D014750:Vincristine; D014700:Verapamil